California-based biotech Halozyme Therapeutics (Nasdaq: HALO) yesterday revealed it has filed a patent infringement lawsuit ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

- This May 1, 2018, shows Merck corporate headquarters in Kenilworth, N.J. RAHWAY, Nj – In its fourth quarter report, Merck, the giant pharmaceutical company with multiple facilities in eastern ...

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

Merck CEO Rob Davis told investors on Thursday that he’s confident in the company’s ability to protect its top-selling ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment landscape for head and neck and lung cancer, and implications for specific drug ...

Patients will likely eventually see higher prices and drug shortages under President Trump's plan to assess tariffs on ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate ...

Healthcare companies rose after earnings from one Big Pharma company. Merck shares ticked up after the drug giant posted quarterly revenue ahead of Wall Street targets, lifted by growth in sales of ...